SAVA - NASDAQ
Cassava Sciences, Inc.
$1.96
-6.5%Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
At a Glance
Live Snapshotsava
Cash at End of Period
Last Annual Value
95.50M
3-Year CAGR
-22%
5-Year CAGR
%
10-Year CAGR
12%
Cassava Sciences, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Cassava Sciences, Inc. NASDAQ:SAVA | 95.50M | -7.6% | -16.4% | 19.1% | |
 PepGen Inc. NASDAQ:PEPG | 62.06M | -9.0% | -14.3% | N/A | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 56.85M | 10.7% | -17.5% | -4.3% | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 58.45M | 43.4% | 5.1% | 7.4% | |
 Codexis, Inc. NASDAQ:CDXS | 52.88M | -7.4% | -15.0% | 10.6% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 29.16M | 28.0% | 2.6% | 6.7% | |
 Immuneering Corporation NASDAQ:IMRX | 128.65M | 29.4% | 11.4% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 226.69M | 4.2% | -16.0% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 26.08M | 15.5% | N/A | N/A | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 34.69M | 4.3% | 28.4% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 16.89M | 14.9% | -42.8% | N/A |
Cassava Sciences, Inc. Fair Value Envelope
Related Guides
Continue your SAVA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.